Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Cash from Operations (2020 - 2025)

Historic Cash from Operations for Tarsus Pharmaceuticals (TARS) over the last 6 years, with Q3 2025 value amounting to $18.3 million.

  • Tarsus Pharmaceuticals' Cash from Operations rose 31101.48% to $18.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$54.0 million, marking a year-over-year increase of 4613.4%. This contributed to the annual value of -$83.0 million for FY2024, which is 2933.45% up from last year.
  • As of Q3 2025, Tarsus Pharmaceuticals' Cash from Operations stood at $18.3 million, which was up 31101.48% from -$29.4 million recorded in Q2 2025.
  • Tarsus Pharmaceuticals' 5-year Cash from Operations high stood at $20.6 million for Q2 2021, and its period low was -$39.3 million during Q4 2023.
  • For the 5-year period, Tarsus Pharmaceuticals' Cash from Operations averaged around -$14.6 million, with its median value being -$15.3 million (2022).
  • The largest annual percentage gain for Tarsus Pharmaceuticals' Cash from Operations in the last 5 years was 90371.53% (2021), contrasted with its biggest fall of 49088.18% (2021).
  • Over the past 5 years, Tarsus Pharmaceuticals' Cash from Operations (Quarter) stood at -$12.1 million in 2021, then rose by 10.29% to -$10.9 million in 2022, then crashed by 261.73% to -$39.3 million in 2023, then soared by 43.61% to -$22.2 million in 2024, then surged by 182.31% to $18.3 million in 2025.
  • Its last three reported values are $18.3 million in Q3 2025, -$29.4 million for Q2 2025, and -$20.7 million during Q1 2025.